These mutational profiles guided different targeted therapy strategies, especially for EGFR. In summary, the patient clinical characteristics (Table S1) including age, sex, duration of disease, primary LUAD site, metastatic sites in LMs (Figure 3A) or other tissues and organs, therapies received before sample collection and tumor mutational profile (Table S4), were different and comparable, contributing to observed transcriptome heterogeneity of CSF‐CTCs among five LUAD‐LM patients. This evidence concerns the gene EGFR and lymphangioma.